Cell-targeted PD-1 agonists that mimic PD-L1 are potent T cell inhibitors

Cell-targeted PD-1 agonists that mimic PD-L1 are potent T cell inhibitors

The PD-1/PD-L1 pathway is a key immune checkpoint that regulates T cell activation. There is strong rationale to develop PD-1 agonists as therapeutics against autoimmunity, but progress in this area has been limited. Here, we generated T cell receptor (TCR) targeting, PD-1 agonist bispecifics called...

Full description

Bibliographic Details
Main Authors: Adam P. Curnock, Giovanna Bossi, Jyothi Kumaran, Lindsay J. Bawden, Rita Figueiredo, Rajeevkumar Tawar, Katherine Wiseman, Emma Henderson, Sec Julie Hoong, Veronica Gonzalez, Hemza Ghadbane, David E.O. Knight, Ronan O’Dwyer, David X. Overton, Christina M. Lucato, Nicola M.G. Smith, Carlos R. Reis, Keith Page, Lorraine M. Whaley, Michelle L. McCully, Stephen Hearty, Tara M. Mahon, Peter Weber
Format: Article
Language:English
Published: American Society for Clinical investigation 2021-10-01
Series:JCI Insight
Subjects:
Autoimmunity
Immunology
Online Access:https://doi.org/10.1172/jci.insight.152468

Internet

https://doi.org/10.1172/jci.insight.152468

Similar Items